HIV prevention drug lenacapavir could dramatically reduce new infections worldwide, yet USAID cuts are preventing access for those most in need, according to experts at the Aids 2026 Conference in Rio de Janeiro. This injectable PrEP requires only two doses per year, offering a breakthrough for vulnerable populations. However, the dissolution of USAID has slashed 73% of donor-funded HIV prevention resources, leaving millions at risk.
Why Lenacapavir Is a Game-Changer in HIV Prevention
Lenacapavir, an injectable HIV prevention medication, is 99% effective in preventing sexually transmitted HIV when taken consistently. Unlike daily oral PrEP pills or bimonthly injections, lenacapavir requires just two injections annually. This makes it ideal for individuals facing poverty, stigma, or living in remote areas with limited healthcare access.
Get the #1 Wireless Door Camera
REOLINK Bestseller: 2K Weatherproof Video Doorbell, No Monthly Fees.
The World Health Organization (WHO) recommended in 2025 that governments prioritize scaling up lenacapavir availability. A mathematical model by WHO and the United Nations estimates that widespread use could prevent 41% of new HIV infections in South Africa, Zimbabwe, and western Kenya.
How Lenacapavir Compares to Current PrEP Options
| PrEP Method | Dosing Frequency | Effectiveness | Access Barriers |
|---|---|---|---|
| Daily Oral Pill | Daily | 99% (if consistent) | Requires daily adherence, refrigeration, and regular refills |
| Bimonthly Injection | Every 2 months | 99% | Requires clinic visits every 2 months, may be hard for rural populations |
| Lenacapavir | Twice a year | 99% | Limited availability outside clinical trials, high cost |
Impact of USAID Cuts on Global HIV Prevention
USAID historically provided 73% of donor-funded resources for HIV prevention globally, according to a study in the Lancet Global Health. As of July 2026, the Trump administration has dissolved USAID, leading to a dramatic decline in HIV prevention investment. This has halted distribution of lenacapavir and other PrEP medications in low-income countries.
Experts warn that without funding, the 41% infection reduction projected by modeling will not materialize. The most affected regions include sub-Saharan Africa, where HIV prevalence is highest and healthcare infrastructure is weakest.
Key Takeaways for Policymakers and Advocates
- Lenacapavir offers a twice-yearly injection that could overcome adherence and access barriers.
- WHO recommends global investment in lenacapavir, but USAID cuts have reduced donor funding by 73%.
- Mathematical modeling shows a potential 41% reduction in new HIV cases in high-burden areas.
- Immediate action is needed to restore funding and ensure equitable access to HIV prevention.
What Can Be Done to Restore Access?
Alternative funding sources, such as the Global Fund and private philanthropy, are being explored, but they currently cannot replace USAID's contribution. Advocacy groups are calling for international cooperation and emergency funding to bridge the gap.
Healthcare providers in affected regions are reporting stockouts of PrEP medications, and new lenacapavir shipments have been cancelled. Without urgent intervention, the global goal of ending AIDS by 2030 is at risk.
FAQ
What is lenacapavir and how does it work for HIV prevention?
Lenacapavir is an injectable PrEP medication that requires only two doses per year. It is 99% effective in preventing sexually transmitted HIV when taken as prescribed, offering a more convenient alternative to daily pills or bimonthly injections.
Why are USAID cuts affecting access to HIV prevention drugs?
USAID provided 73% of donor-funded resources for global HIV prevention. Its dissolution has led to a dramatic decline in funding, halting the distribution of lenacapavir and other PrEP medications in low-income countries, leaving millions without access.
What is the potential impact of lenacapavir on global HIV rates?
According to WHO and UN modeling, widespread availability of lenacapavir could prevent 41% of new HIV infections in South Africa, Zimbabwe, and western Kenya. However, this requires sustained funding and distribution efforts.